PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Insulin Efsitora Alfa→

Insulin Efsitora Alfa PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2131038-11-2
Molecular formula
C2810H4296N776O882S32
Molecular weight
64090 g/mol
Drug class
Long-acting basal insulin analogueantidiabetic hormone
Mechanism of action
Activates insulin receptors to regulate glucose metabolism, increasing peripheral glucose uptake (especially in skeletal muscle and adipose tissue) and suppressing hepatic glucose production. Its prolonged weekly action reflects reduced renal clearance, FcRn binding and reduced insulin-receptor affinity relative to human insulin.
Indications / reported uses
  • Improvement of glycaemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise, under the current product label.

Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e02229e-262c-4e25-9240-9e9de4eb7c1d · https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-once-weekly-insulin-type-2-diabetes-mellitus · https://www.ema.europa.eu/en/medicines/human/EPAR/onswik

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Insulin Efsitora Alfa PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Insulin Efsitora Alfa Permitted Daily Exposure (PDE) report (the Insulin Efsitora Alfa PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Insulin Efsitora Alfa Occupational Exposure Limit (OEL) report (the Insulin Efsitora Alfa OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.